ipilimumab,nivolumab,cabozantinib
exelixis,bms
['nivo', 'cabozantinib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic-313', 'ipilimumab', 'nivolumab', 'renal,(-adrenal)']
phase 3 study of cabozantinib (c) in combination with nivolumab (n) and ipilimumab (i) in previously untreated advanced renal cell carcinoma (arcc) of imdc intermediate or poor risk (cosmic-313) #esmo22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis